{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:37:34Z","timestamp":1792820254411,"version":"4.5.0"},"reference-count":19,"publisher":"Japanese Urological Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2026,10,20]]},"DOI":"10.5980\/jpnjurol.117.123","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:11:48Z","timestamp":1792447908000},"page":"123-127","source":"Crossref","is-referenced-by-count":0,"title":["EARLY DETECTION OF BONE METASTASIS BY WHOLE-BODY MRI AND TRIPLET THERAPY AFTER RADICAL PROSTATECTOMY: A CASE REPORT","RARP\u8853\u5f8c\u65e9\u671fPSA\u4e0a\u6607\u306b\u5bfe\u3057\u3066WBMRI\u3067\u9aa8\u8ee2\u79fb\u3092\u691c\u51fa\u3057Triplet\u7642\u6cd5\u3092\u5c0e\u5165\u3057\u305f\u9ad8\u30ea\u30b9\u30af\u524d\u7acb\u817a\u764c\u306e\u4e00\u4f8b"],"prefix":"10.5980","volume":"117","author":[{"given":"Yuki","family":"Shimoma","sequence":"first","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Morozumi","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Sawai","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kaiho","sequence":"additional","affiliation":[{"name":"Department of Urology, Tohoku Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL and Cookson MS: Advanced Prostate Cancer: AUA\/ASTRO\/SUO Guideline PART I. J Urol., 205 (1), 14-21, 2021.","DOI":"10.1097\/JU.0000000000001375"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvi\u00e8re O, Schoots IG, Tilki D, Wiegel T, Willemse PM and Cornford P: EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol., 79 (2), 243-262, 2021.","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J and Freedman-Cass DA: Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw., 21 (10), 1067-1096, 2023.","DOI":"10.6004\/jnccn.2023.0050"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC and Cookson MS: Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023). J Urol., 209 (6), 1082-1090, 2023.","DOI":"10.1097\/JU.0000000000003452"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S and Murphy DG: Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet., 395 (10231), 1208-1216, 2020.","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Michoux NF, Ceranka JW, Vandemeulebroucke J, Peeters F, Lu P, Absil J, Triqueneaux P, Liu Y, Collette L, Willekens I, Brussaard C, Debeir O, Hahn S, Raeymaekers H, de Mey J, Metens T and Lecouvet FE: Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study. Eur Radiol., 31 (7), 4514-4527, 2021.","DOI":"10.1007\/s00330-020-07522-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kohada Y, Satani N, Kaiho Y, Iwamura H, Sakamoto T, Kusumoto H, Kukimoto T, Oikawa M, Mikami J, Ito J, Matsuura T, Hinata N, Koyama K and Sato M: Novel quantitative software for automatically excluding red bone marrow on whole-body magnetic resonance imaging in patients with metastatic prostate cancer: A pilot study. Int J Urol., 30 (4), 356-364, 2023.","DOI":"10.1111\/iju.15124"},{"key":"8","unstructured":"8) \u5ca9\u6751\u5927\u5f84: Whole-body MRI\u306b\u3088\u308b\u8ee2\u79fb\u6027\u524d\u7acb\u817a\u304c\u3093\u306e\u816b\u760d\u91cf\u5b9a\u91cf\u5316\u306e\u8ab2\u984c\u3068\u4eca\u5f8c\u306e\u5c55\u671b. \u897f\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1, 85, 1-6, 2022."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T, Suzuki K, Shinmoto H, Tamada T, Inoue T, Sugimoto M, Takenaka A, Habuchi T, Ishikawa H, Mizowaki T, Saito S, Miyake H, Matsubara N, Nonomura N, Sakai H, Ito A, Ukimura O, Matsuyama H and Hara I: Japanese clinical practice guidelines for prostate cancer 2023. Int J Urol., 31 (11), 1180-1222, 2024.","DOI":"10.1111\/iju.15545"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Pricolo P, Ancona E, Summers P, Abreu-Gomez J, Alessi S, Jereczek-Fossa BA, De Cobelli O, Nol\u00e8 F, Renne G, Bellomi M, Padhani AR and Petralia G: Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. Cancer Imaging., 20 (1), 77, 2020.","DOI":"10.1186\/s40644-020-00350-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Freedland SJ, Gao W, Lax A, Yang H, Ramaswamy K, Russell D, Hong A and Ivanova JI: Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. Prostate Cancer Prostatic Dis., 28 (3), 809-816, 2025.","DOI":"10.1038\/s41391-024-00894-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Iwamura H, Kaiho Y, Ito J, Anan G, Satani N, Matsuura T, Tamura R, Murakami K, Koyama K and Sato M: Evaluation of Tumor Viability for Primary and Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole-Body Magnetic Resonance Imaging. Case Rep Urol., 2018, 4074378, 2018.","DOI":"10.1155\/2018\/4074378"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Padhani AR, Koh DM and Collins DJ: Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology., 261 (3), 700-718, 2011.","DOI":"10.1148\/radiol.11110474"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ketelsen D, R\u00f6thke M, Aschoff P, Merseburger AS, Lichy MP, Reimold M, Claussen CD and Schlemmer HP: [Detection of bone metastasis of prostate cancer - comparison of whole-body MRI and bone scintigraphy]. Rofo, 180 (8), 746-752, 2008.","DOI":"10.1055\/s-2008-1027479"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J and Parmar MK: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (London, England), 387 (10024), 1163-1177, 2016.","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino \u00c1, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, M\u00e9ndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I and Tombal B: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med., 386 (12), 1132-1142, 2022.","DOI":"10.1056\/NEJMoa2119115"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, T\u00fcrkeri LN, Uemura H, \u00dcr\u00fcn Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A and Omlin A: Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol., 87 (2), 157-216, 2025.","DOI":"10.1016\/j.eururo.2024.09.017"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Morozumi K, Mitsuzuka K, Narita S, Takahashi M, Kawamura S, Tochigi T, Arai Y, Hoshi S, Shimoda J, Ishidoya S, Okamoto T, Hatakeyama S, Sakurai T, Tsuchiya N, Ohyama C, Habuchi T and Ito A: Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score \u22658. International journal of urology: official journal of the Japanese Urological Association., 29 (4), 324-331, 2022.","DOI":"10.1111\/iju.14781"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Marvaso G, Corrao G, Zaffaroni M, Vincini MG, Lorubbio C, Gandini S, Fodor C, Netti S, Zerini D, Luzzago S, Mistretta FA, Venetis K, Cursano G, Burla T, Mazzocco K, Cattani F, Petralia G, Fusco N, Pravettoni G, Musi G, De Cobelli O, Tang C, Ost P, Palma DA, Orecchia R and Jereczek-Fossa BA: ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol., 26 (3), 300-311, 2025.","DOI":"10.1016\/S1470-2045(24)00730-7"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/4\/117_123\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:56:07Z","timestamp":1792817767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/4\/117_123\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.117.123","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}